Study wrapper · #1387
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Editor's note
A narrative review, but one that assembles genuinely current material: SUMMIT cardiac-MRI data showing reverse ventricular remodelling with tirzepatide, and isolated human atrial tissue work showing direct inotropic effects of retatrutide. The retatrutide cardiovascular story remains surrogate-only until TRIUMPH outcome data report, which the authors acknowledge. A useful synthesis of the mechanism-beyond-glycemia argument.
Plain-language abstract
A review of how GLP-1 drugs, tirzepatide, and triple agonists like retatrutide affect the cardiovascular system, arguing that less than a fifth of their cardiovascular benefit comes from blood-sugar control — the rest reflects weight, blood pressure, lipids, inflammation, and direct effects on heart muscle.